Citius Oncology, Inc.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Citius Oncology, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +5 vs. Q1 2026
- Shares held
- 14.1M
- −102.5K (−0.7%) vs. Q1 2026
- Total value
- $9.20M
- +$366.4K (+4.2%) vs. Q1 2026
- New holders
- 7
- 2 more added
- Sold out
- 2
- 3 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CTOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $9.20M |
| Q1 2026 | 14 | $8.83M |
| Q4 2025 | 18 | $6.86M |
| Q3 2025 | 16 | $17.0M |
| Q2 2025 | 7 | $989.6K |
| Q1 2025 | 6 | $97.7K |
| Q4 2024 | 11 | $230.2K |
| Q3 2024 | 7 | $57.0K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Citius Oncology, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 8,705,589 | $5.66M | 0.16% | −483,266−5.3% | Reduced |
| Bank of America Corp | 3,835,160 | $2.49M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 546,325 | $355.1K | 0.00% | +11,501+2.2% | Added |
| UBS Group AG | 334,619 | $217.5K | 0.00% | +297,779+808.3% | Added |
| Geode Capital Management, LLC | 245,407 | $159.5K | 0.00% | −19,326−7.3% | Reduced |
| Vanguard Fiduciary Trust Co | 121,910 | $79.2K | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 107,424 | $69.8K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 90,586 | $58.9K | 0.00% | +90,586 | New |
| Northern Trust Corp | 45,746 | $29.7K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 42,900 | $27.9K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 21,877 | $14.0K | 0.00% | +21,877 | New |
| XTX Topco Ltd | 20,638 | $13.4K | 0.00% | +20,638 | New |
| Tower Research Capital LLC (TRC) | 13,816 | $8.98K | 0.00% | +13,816 | New |
| Arkadios Wealth Advisors | 11,666 | $7.58K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1,000 | $650 | 0.00% | −9,125−90.1% | Reduced |
| Wells Fargo & Company | 500 | $325 | 0.00% | +500 | New |
| Barclays PLC | 90 | $59 | 0.00% | +90 | New |
| Morgan Stanley | 23 | $15 | 0.00% | +23 | New |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 0 | $0 | 0.00% | −47,454−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −186−100.0% | Sold out |